Regulus Therap (NASDAQ: RGLS) reported Q2 EPS of ($0.29), $0.10 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $3.19 million.

For earnings history and earnings-related data on Regulus Therap (RGLS) click here.